VEGFA Polyclonal Antibody

catalog number: E-AB-19306



Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

Reactivity Human

Immunogen Synthetic peptide of human VEGFA

Host Rabbit IgG **Isotype**


Purification Antigen affinity purification

Unconjugated Conjugation

buffer Phosphate buffered solution, pH 7.4, containing 0.05% stabilizer and 50% glycerol.

Applications	Recommended Dilution	
WB	1:1000-1:5000	
IHC	1.25-1.100	


Data



using VEGFA Polyclonal Antibody at dilution of 1:1050

Western blot analysis of 293T K562 and NIH/3T3 cell lysates Immunohistochemistry of paraffin-embedded Human liver cancer tissue using VEGFA Polyclonal Antibody at dilution of 1:45(×200)

Observed-MV: Refer to figures



Immunohistochemistry of paraffin-embedded Human tonsil tissue using VEGFA Polyclonal Antibody at dilution of 1:45(×200)

Preparation & Storage

Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. Storage

Shipping The product is shipped with ice pack, upon receipt, store it immediately at the

temperature recommended.

Background

For Research Use Only

VEGFA Polyclonal Antibody

catalog number: E-AB-19306



This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site.